Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects.
about
Tracking Inhibitory Alterations during Interstrain Clostridium difficile Interactions by Monitoring Cell Envelope Capacitance.Dielectrophoretic monitoring and interstrain separation of intact Clostridium difficile based on their S(Surface)-layers.Clostridium difficile and the microbiotaSusceptibility of hamsters to Clostridium difficile isolates of differing toxinotype.Prevalence of Clostridium difficile colonization among healthcare workers.Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazoleRecurrent Clostridium difficile infection: From colonization to cure.Clostridium difficile drug pipeline: challenges in discovery and development of new agentsNovel approaches to treating Clostridium difficile-associated colitis.Breakthroughs in the treatment and prevention of Clostridium difficile infection.Comparative genomic analysis of toxin-negative strains of Clostridium difficile from humans and animals with symptoms of gastrointestinal diseaseThe non-toxigenic Clostridium difficile CD37 protects mice against infection with a BI/NAP1/027 type of C. difficile strain.A clinical and epidemiological review of non-toxigenic Clostridium difficile.Comparison of perirectal versus rectal swabs for detection of asymptomatic carriers of toxigenic Clostridium difficileClostridium difficile infection in the twenty-first century.Clostridium difficile infection: management strategies for a difficult disease.Novel avenues for Clostridium difficile infection drug discovery.Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection.Antibodies for treatment of Clostridium difficile infection.Mobile genetic elements in Clostridium difficile and their role in genome function.Prevention of Clostridium difficile Infection With Probiotics.Pathogenesis of Clostridium difficile Infection and Its Potential Role in Inflammatory Bowel Disease.Mucosal Antibodies to the C Terminus of Toxin A Prevent Colonization of Clostridium difficile.Therapies on the horizon for Clostridium difficile infections.Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers.An Evaluation of Food as a Potential Source for Clostridium difficile Acquisition in Hospitalized Patients.Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?Complete genome sequence of Peptoclostridium difficile strain Z31.Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficileTherapeutic approaches for Clostridium difficile infections.Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection.Modeling Host-Microbiome Interactions in Caenorhabditis elegans.Advances in the diagnosis and treatment of Clostridium difficile infections.
P2860
Q27300282-5412882A-F6D0-4454-8117-B388070DC84AQ30303057-37E4D876-15B3-4E12-A4D8-A8813C5732A3Q34311594-971C4084-5034-429B-A062-60536303B1BDQ34737968-EFC2E189-5D57-46CA-B82C-C5E766D317C6Q35007344-A0F9D729-81DD-4C08-AC49-C022D15B88ABQ35009326-34AA8C6B-24FF-43BB-A79A-955882FA59E7Q35822541-1CBAB84E-538A-4725-83E9-50D95A8041DFQ35846436-EA621482-F41B-4CF9-92E3-8E5A0060B868Q35862915-66B4F1AD-D56E-460D-B9D5-6947F0AA9275Q35918566-15EE85C7-515F-415E-8037-B5A756789B38Q35955254-7AC7E210-C5C5-496D-98E6-4E9E54307501Q36328439-1CAE07E8-C40B-47D6-A3CC-D58AC4478CF9Q37060179-83D0CEE4-FDAC-46F0-AC99-CF596FF0505EQ37264328-DD68EF5A-9EF6-466C-8247-BED98AAEAD13Q37289567-1B90C321-CFDB-40C5-B82F-958D698DBC40Q37519138-ABA2156A-0E1C-42D4-A3DC-B2682C162FDCQ38083297-14174702-3833-4398-8888-6E962F2B1453Q38130644-8E073CDA-1DA0-48BD-9502-A1871AB84459Q38208794-6045FEC3-5A4E-40F6-B0BF-8E4352606F7BQ38313613-14FD18DD-1885-4FB8-A48B-1D1C9FB2F955Q38448285-1F1DB874-789A-471E-AF6F-0916E9521A9FQ38551892-B4F807FF-488B-4EFE-8B33-9B2800F4678CQ38717600-A7C15D97-5F5D-48F1-8B9B-F452F82A064DQ38757930-4C4FED84-72D0-4BEA-94A5-D92212D8C561Q38794312-C3E71F38-E886-4542-B98C-E61BE41C7FD2Q39077747-FF296933-FBE7-423A-92E7-C9576008D65AQ39333576-BAF601A1-B013-4C74-82EF-9710B84BDB86Q40110130-00F093F0-EE23-4B89-8ABA-514B07CA7D55Q40735474-92E6B2F7-4821-4D49-BB7E-F1EF1E18995DQ42110052-2D1F7490-2AF8-424D-9D60-8775E66C8011Q45406068-55134055-0094-43A8-9373-F88C0386B4D9Q47707104-F50F87A3-F153-4154-A48E-9747AA4AF0AAQ49403382-9315C6A6-A2A5-4EB9-B8FF-E4B6CB9D2F52Q50055623-941F5063-1CCD-4D52-AAE0-C98498F80300
P2860
Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Evaluation of an oral suspensi ...... train M3, in healthy subjects.
@ast
Evaluation of an oral suspensi ...... train M3, in healthy subjects.
@en
type
label
Evaluation of an oral suspensi ...... train M3, in healthy subjects.
@ast
Evaluation of an oral suspensi ...... train M3, in healthy subjects.
@en
prefLabel
Evaluation of an oral suspensi ...... train M3, in healthy subjects.
@ast
Evaluation of an oral suspensi ...... train M3, in healthy subjects.
@en
P2093
P2860
P356
P1476
Evaluation of an oral suspensi ...... train M3, in healthy subjects.
@en
P2093
Elizabeth Monnot-Chase
Michael Seiberling
Stephen A Villano
Walter Tatarowicz
P2860
P304
P356
10.1128/AAC.00913-12
P407
P577
2012-07-30T00:00:00Z